Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 16/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19401267 | 0.94 | NR1H4 (0.50) | NR1H4CXCR3 | |
| SCHEMBL16701999 | 0.85 | NR1H4 (0.73) | NR1H4MRGPRX4 | |
| SCHEMBL16702377 | 0.80 | NR1H4 (0.69) | NR1H4MRGPRX4EIF4EBP1 | |
| SCHEMBL16702125 | 0.80 | NR1H4 (0.63) | NR1H4EIF4EBP1 | |
| SCHEMBL16702648 | 0.79 | NR1H4 (0.66) | NR1H4 | |
| SCHEMBL16702362 | 0.78 | NR1H4 (0.68) | NR1H4 | |
| SCHEMBL16701974 | 0.76 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL16702178 | 0.76 | NR1H4 (0.59) | NR1H4 | |
| SCHEMBL19910475 | 0.75 | NR1H4 (0.60) | NR1H4 | |
| SCHEMBL16703486 | 0.75 | NR1H4 (0.64) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20170275256-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885EIF4EBP1 1231/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885EIF4EBP1 1231/4885 |
| US-20170275256-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885EIF4EBP1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.